7:50 PM Oct 19, 2018
BioCentury  |  Product Development

New shops for value-based deals

Value-based payment models are starting to appear beyond the high-profile insurers and PBMs that have dominated the scene, with a series of deals struck since August by the Oklahoma Health Care...

Read More
6:04 PM Oct 19, 2018
BioCentury  |  Politics, Policy & Law

PhRMA and Trump: war or peace?

HHS Secretary Alex Azar’s proposal to require price disclosures in television advertisements for drugs is forcing the biopharma industry to think hard about its relationship with the Trump...

Read More
3:46 PM Oct 19, 2018
BioCentury  |  Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...

Read More
5:36 PM Oct 18, 2018
BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers...

Read More
4:44 PM Oct 18, 2018
BC Innovations  |  Targets & Mechanisms

Volkow: why pain and addiction will go personalized

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic...

Read More
1
2
3
4
5

Latest News

4:38 PM Oct 19, 2018

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

EMA’s CHMP recommended several approvals Friday, including hereditary angioedema (HAE) mAb Takhzyro...

Read More
4:32 PM Oct 19, 2018

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Friday that FDA and EMA have both pushed back their reviews of...

Read More
3:47 PM Oct 19, 2018

Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily Rubraca rucaparib led to a confirmed objective...

Read More
3:42 PM Oct 19, 2018

FDA approves Dupixent for asthma

FDA approved Dupixent dupilumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (...

Read More
3:35 PM Oct 19, 2018

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately,...

Read More
3:27 PM Oct 19, 2018

FDA asks peers to globalize generic drug development

FDA is calling on international regulatory authorities to develop harmonized guidelines on scientific and...

Read More
12:25 PM Oct 19, 2018

LogicBio marks week’s third IPO to miss price target

LogicBio Therapeutics Inc. (NASDAQ:LOGC) priced its IPO below its proposed range late Thursday, joining...

Read More
9:52 AM Oct 19, 2018

Study uncovers large batch effects in TCGA exome sequencing data

A preprint article published in bioRxiv identified large cross-institutional batch effects for a subset of...

Read More
5:26 AM Oct 19, 2018

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and...

Read More
3:37 PM Oct 18, 2018

CMS’s Verma outlines new drug payment options

CMS Administrator Seema Verma Thursday outlined three types of payment arrangements the agency is...

Read More
3:14 PM Oct 18, 2018

Big gain for Proteostasis on Phase I data for CF doublet

Proteostasis Therapeutics Inc. (NASDAQ:PTI) jumped $8.46 (448%) to $10.35 on Thursday after reporting that...

Read More
3:09 PM Oct 18, 2018

AbbVie, Morphic partner on antifibrotic integrins

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for...

Read More
3:07 PM Oct 18, 2018

UC Berkeley group identifies new Cas enzyme

In a Science paper published Thursday, Jennifer Doudna's lab reported a new family of CRISPR-associated...

Read More
1:10 PM Oct 18, 2018

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program...

Read More
12:57 PM Oct 18, 2018

Management tracks: Autolus, Bayer, Cambridge Allergy

T cell cancer therapy company Autolus Therapeutics plc (NASDAQ:AUTL) hired Adam Hacker as SVP for...

Read More
11:48 AM Oct 18, 2018

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) lost $2.85 (17%) to $13.86 on Thursday after it voluntarily...

Read More
11:00 AM Oct 18, 2018

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the...

Read More
10:47 AM Oct 18, 2018

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1...

Read More
9:50 AM Oct 18, 2018

Flurry of news highlights latest in switch-controlled gene therapy

A series of company announcements signal advances in switch-controlled gene therapy.

Read More
7:01 AM Oct 18, 2018

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer...

Read More
Down Up